Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Jeena Jacob
Institution:
The University of Texas Medical Branch at Galveston
Observed institution:
The University of Texas Medical Branch at Galveston
ORCID:
0009-0002-2217-2543
Observed ORCID:
0009-0002-2217-2543
OpenAlex ID:
A5137798330
From Stress to Survival: Trophoblast-Derived Extracellular Vesicle Proteome Captures Aspirin-Driven Cellular Reprogramming in a Preeclampsia Model
2026
·
Vineet Mahajan
, Awanit Kumar
, et al.
·
Pharmaceutics
·
1
Data from Proteogenomic Profiling Identifies FGFR2b as a Prevalent Cell Surface Target in Intrahepatic Cholangiocarcinoma
2026
·
Nakul M. Shah
, Beatriz Alvarado-Hernandez
, et al.
Supplementary Tables1 from Proteogenomic Profiling Identifies FGFR2b as a Prevalent Cell Surface Target in Intrahepatic Cholangiocarcinoma
2026
·
Nakul M. Shah
, Beatriz Alvarado-Hernandez
, et al.
Supplementary Figures1 from Proteogenomic Profiling Identifies FGFR2b as a Prevalent Cell Surface Target in Intrahepatic Cholangiocarcinoma
2026
·
Nakul M. Shah
, Beatriz Alvarado-Hernandez
, et al.
Supplementary Figure S5 from Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma
2026
·
Kai Yu
, Rebecca S. Tidwell
, et al.
Supplementary Table S5 from Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma
2026
·
Kai Yu
, Rebecca S. Tidwell
, et al.
Supplementary Appendix S1 from Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma
2026
·
Kai Yu
, Rebecca S. Tidwell
, et al.
Supplementary Figure S3 from Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma
2026
·
Kai Yu
, Rebecca S. Tidwell
, et al.
Supplementary Figure S4 from Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma
2026
·
Kai Yu
, Rebecca S. Tidwell
, et al.
Supplementary Table S10 from Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma
2026
·
Kai Yu
, Rebecca S. Tidwell
, et al.
Supplementary Table S2 from Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma
2026
·
Kai Yu
, Rebecca S. Tidwell
, et al.
Supplementary Table S9 from Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma
2026
·
Kai Yu
, Rebecca S. Tidwell
, et al.
Supplementary Table S11 from Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma
2026
·
Kai Yu
, Rebecca S. Tidwell
, et al.
Supplementary Table S4 from Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma
2026
·
Kai Yu
, Rebecca S. Tidwell
, et al.
Supplementary Table S7 from Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma
2026
·
Kai Yu
, Rebecca S. Tidwell
, et al.
Supplementary Figure S6 from Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma
2026
·
Kai Yu
, Rebecca S. Tidwell
, et al.
Supplementary Table S8 from Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma
2026
·
Kai Yu
, Rebecca S. Tidwell
, et al.
Supplementary Table S1 from Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma
2026
·
Kai Yu
, Rebecca S. Tidwell
, et al.
Supplementary Figure S7 from Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma
2026
·
Kai Yu
, Rebecca S. Tidwell
, et al.
Supplementary File S1 from Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma
2026
·
Kai Yu
, Rebecca S. Tidwell
, et al.
Supplementary Table S3 from Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma
2026
·
Kai Yu
, Rebecca S. Tidwell
, et al.
Supplementary Table S6 from Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma
2026
·
Kai Yu
, Rebecca S. Tidwell
, et al.
Supplementary Figure S8 from Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma
2026
·
Kai Yu
, Rebecca S. Tidwell
, et al.
Supplementary Figure S2 from Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma
2026
·
Kai Yu
, Rebecca S. Tidwell
, et al.
Supplementary Figure S1 from Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma
2026
·
Kai Yu
, Rebecca S. Tidwell
, et al.
Show more works
View as search
Works count:
47
Citation count:
1
H-index:
1
I10-index:
Year
Topic
Type